News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Phase 3 Clinical Trial of GlaxoSmithKline (GSK)'s Herpes Zoster Vaccine Candidate Containing Agenus (Formerly known as Antigenics Inc. - Lexington, MA) (AGEN)' QS-21 Commences in Immunocompromised Patients



7/18/2012 9:25:30 AM

LEXINGTON, Mass., July 18, 2012 (GLOBE NEWSWIRE) -- Agenus, Inc. (Nasdaq:AGEN) today announced that GlaxoSmithKline's (GSK) herpes zoster vaccine candidate (HZ/su), which contains Agenus' QS-21 Stimulon®1 adjuvant as a component of GSK's adjuvant system, has commenced a global, randomized, placebo-controlled Phase 3 clinical trial for the prevention of shingles (herpes zoster) in immunocompromised patients. This study will include approximately 200 clinical sites and enroll more than 1,400 patients 18 years of age or older undergoing hematopoietic stem cell transplantation (HCT). Herpes zoster, which can occur as a complication of HCT, has limited treatment and prevention options available.

Read at GlobeNewswire


comments powered by Disqus
   
Shingles

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES